专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012009447A2 THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF 审中-公开
标题翻译： cAMP / PKA / HDAC5途径及其用途
公开(公告)号：WO2012009447A2
公开(公告)日：2012-01-19
申请号：PCT/US2011/043873
申请日：2011-07-13
申请人： UNIVERSITY OF ROCHESTER , JIN, Zheng-gen
发明人： JIN, Zheng-gen
IPC分类号： A61K38/10 , A61K39/395 , A61K31/7105 , C07K7/08 , C12N15/63 , C12N15/113 , A61P9/04 , A61P9/00
CPC分类号： A61K39/39533 , A61K31/352 , A61K31/7076 , A61K31/7088 , A61K31/7105 , A61K38/10 , C07K16/40 , C12N15/1137 , C12N2310/14 , C12Y207/11011 , G01N33/5061 , G01N33/573 , G01N2333/98 , G01N2440/14 , G01N2500/04 , G01N2500/10 , G01N2800/325
摘要： The present invention provides novel uses of the cAMP/PKA/HDAC5 pathway for the treatment and prevention of myopathies.
摘要翻译：本发明提供了cAMP / PKA / HDAC5途径用于治疗和预防肌病的新用途。

2. 发明申请

WO2014028560A2 T-CELL REDIRECTING BISPECIFIC ANTIBODIES FOR TREATMENT OF DISEASE 审中-公开
标题翻译： T细胞重定向治疗疾病的双重抗体
公开(公告)号：WO2014028560A2
公开(公告)日：2014-02-20
申请号：PCT/US2013/054842
申请日：2013-08-14
申请人： IBC PHARMACEUTICALS, INC.
发明人： CHANG, Chien-Hsing , GOLDENBERG, David M. , ROSSI, Edmund A. , ROSSI, Diane
IPC分类号： C07K16/18 , A61K38/21 , A61K47/42 , A61K39/395 , A61K45/06 , A61K38/19 , C07K16/28 , C07K16/40 , C07K16/32
CPC分类号： C07K14/001 , A61K9/0019 , A61K38/00 , A61K38/1709 , A61K38/195 , A61K38/21 , A61K38/212 , A61K38/215 , A61K38/217 , A61K38/45 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K47/42 , A61K47/60 , A61K47/64 , A61K2039/505 , A61K2039/572 , C07K14/4702 , C07K16/18 , C07K16/2803 , C07K16/2806 , C07K16/2809 , C07K16/2812 , C07K16/2815 , C07K16/2818 , C07K16/2827 , C07K16/283 , C07K16/2833 , C07K16/2842 , C07K16/2845 , C07K16/2851 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K16/2878 , C07K16/2884 , C07K16/2887 , C07K16/289 , C07K16/2893 , C07K16/2896 , C07K16/30 , C07K16/3007 , C07K16/3053 , C07K16/3076 , C07K16/3092 , C07K16/32 , C07K16/40 , C07K16/44 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30 , C07K2319/33 , C07K2319/40 , C07K2319/735 , C07K2319/74 , C07K2319/75 , C12N9/12 , C12Y207/11001 , C12Y207/11011 , Y02A50/466 , A61K2300/00
摘要： The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3 x anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The the cytotoxic immune response is enhanced by co-administration of interfon-based agents that comprise interferon-α, interferon-β, interferon-λ1, interferon-λ2 or interferon-λ3.
摘要翻译：本发明涉及使用T细胞重定向复合物的组合物和方法，其中至少一个T细胞抗原的结合位点和病变细胞或病原体上的抗原的至少一个结合位点。优选地，复合物是DNL TM复合物。更优选地，复合物包含双特异性抗体（bsAb）。最优选地，bsAb是抗CD3×抗CD19双特异性抗体，尽管可以使用针对其它T细胞抗原和/或疾病相关抗原的抗体。该复合物能够靶向效应T细胞以诱导与疾病如癌症，自身免疫疾病或感染性疾病相关的细胞的T细胞介导的细胞毒性。通过共同施用包含干扰素-α，干扰素-α，干扰素-λ1，干扰素-λ2或干扰素-λ3的基于蛋白质的试剂来增强细胞毒性免疫应答。

3. 发明申请

WO2013181087A2 MULTIMERIC COMPLEXES WITH IMPROVED IN VIVO STABILITY, PHARMACOKINETICS AND EFFICACY 审中-公开
标题翻译：改善体内稳定性，药物动力学和效率的多元复合物
公开(公告)号：WO2013181087A2
公开(公告)日：2013-12-05
申请号：PCT/US2013/042594
申请日：2013-05-24
申请人： IBC PHARMACEUTICALS, INC.
发明人： ROSSI, Edmund A. , CHANG, Chien-Hsing , GOLDENBERG, David M.
IPC分类号： A61K39/395 , C07K16/30 , A61K45/06
CPC分类号： C07K16/3092 , A61K45/06 , A61K47/6813 , A61K47/6815 , A61K47/6817 , A61K47/6829 , A61K47/6849 , A61K2039/505 , C07K14/56 , C07K16/18 , C07K16/2803 , C07K16/2833 , C07K16/2851 , C07K16/2863 , C07K16/2887 , C07K16/3007 , C07K16/44 , C07K2317/24 , C07K2317/30 , C07K2317/32 , C07K2317/526 , C07K2317/55 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/94 , C07K2319/00 , C12N9/12 , C12N9/22 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2320/00 , C12N2320/32 , C12Y207/11011 , C12Y301/27
摘要： The present invention concerns multimeric complexes based on antibody fusion proteins comprising an AD moiety attached to the C-terminal end of each antibody light chain. The complexes further comprise effector moities attached to DDD moieties. Two copies of the DDD moiety form a dimer that binds to the AD moiety. The complexes may be trimers, pentamers, hexamers or other multimers. The effector moieties may be selected from a second antibody or antigen-binding fragment thereof, a cytokine, an interferon, a toxin, an antigen, a xenoantigen, a hapten, a protamine, a hormone, an enzyme, a ligand-binding protein, a pro-apoptotic agent and an anti-angiogenic agent. Surprisingly, attachment of the AD moiety to the C-terminal end of the antibody light chain results in improved pharmacokinetics and in vivo stability and efficacy, compared to homologous complexes wherein the AD moiety is attached to the antibody heavy chain.
摘要翻译：本发明涉及基于抗体融合蛋白的多聚体复合物，其包含连接于每个抗体轻链的C末端的AD部分。复合物还包含与DDD部分连接的效应物。 DDD部分的两个拷贝形成与AD部分结合的二聚体。络合物可以是三聚体，五聚体，六聚体或其它多聚体。效应部分可以选自第二抗体或其抗原结合片段，细胞因子，干扰素，毒素，抗原，异种抗原，半抗原，鱼精蛋白，激素，酶，配体结合蛋白，促凋亡剂和抗血管生成剂。令人惊讶的是，与其中AD部分连接到抗体重链的同源复合物相比，AD部分与抗体轻链的C-末端的连接导致改善的药代动力学和体内稳定性和功效。

4. 发明申请

WO2013092212A1 PEPTIDIC INHIBITOR OF SIGNAL TRANSMISSION FROM G-ALPHA-S TO G-ALPHA-I-COUPLED RECEPTOR CASCADES 审中-公开
标题翻译：从G-ALPHA-S到G-ALPHA-I联合受体载体的信号传递的肽抑制剂
公开(公告)号：WO2013092212A1
公开(公告)日：2013-06-27
申请号：PCT/EP2012/074489
申请日：2012-12-05
申请人： UNIVERSITÄT INNSBRUCK
发明人： STEFAN, Eduard , BACHMANN, Verena , HUBER, Roland
IPC分类号： C12N9/12 , C07K7/08 , A61K38/45
CPC分类号： C07K7/08 , A61K38/00 , A61K38/10 , C07K14/723 , C07K2319/00 , C12N9/12 , C12Y207/11011 , G01N33/5011 , G01N33/54306 , G01N33/6893 , G01N2333/4719 , G01N2333/912 , G01N2500/04 , G01N2800/325
摘要： The present invention relates to novel peptidic inhibitors of signal transmission from Gαs- to Gαi-coupled receptor cascades and methods for their use.
摘要翻译：本发明涉及从Galphas-到Galphai偶联受体级联的信号传递的新型肽抑制剂及其使用方法。

5. 发明申请

WO2010022225A1 DOCK-AND-LOCK (DNL) VACCINES FOR CANCER THERAPY 审中-公开
标题翻译：用于癌症治疗的DOCK-AND-LOCK（DNL）疫苗
公开(公告)号：WO2010022225A1
公开(公告)日：2010-02-25
申请号：PCT/US2009054441
申请日：2009-08-20
申请人： IBC PHARMACEUTICALS INC , CHANG CHIEN-HSING , GOLDENBERG DAVID M
发明人： CHANG CHIEN-HSING , GOLDENBERG DAVID M
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K47/6897 , A61K2039/505 , A61K2039/6056 , A61K2039/625 , B82Y5/00 , C07K16/2803 , C07K16/2833 , C07K16/2887 , C07K16/3007 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/522 , C07K2317/526 , C07K2317/55 , C07K2317/77 , C07K2317/92 , C07K2319/00 , C07K2319/30 , C12Y207/11011
摘要： The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138negCD20+ MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.
摘要翻译：本发明涉及使用对接和锁定技术形成抗癌疫苗DNL复合物的方法和组合物。在优选的实施方案中，抗癌疫苗DNL复合物包含结合到附着于AD（锚定结构域）部分和异种抗原的树突状细胞例如抗CD74抗体或其抗原结合片段的抗体部分，例如 CD20，连接到DDD（二聚化和对接结构域）部分，其中DDD部分的两个拷贝形成结合AD部分的二聚体，导致DNL复合物的形成。抗癌疫苗DNL复合物能够诱导针对异种抗原表达癌细胞的免疫应答，例如CD138negCD20 + MM干细胞，并诱导凋亡并抑制癌细胞的生长或消除癌细胞。

6. 发明申请

WO2016154621A1 SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF 审中-公开
标题翻译：可切换的非scFv子宫颈受体，开关及其用途
公开(公告)号：WO2016154621A1
公开(公告)日：2016-09-29
申请号：PCT/US2016/024524
申请日：2016-03-28
申请人： THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH
发明人： YOUNG, Travis , KIM, Chanhyuk , SCHULTZ, Peter G.
IPC分类号： A61K48/00 , A61K38/17 , A61K35/17 , C07K14/435 , C07K14/32 , C12N15/62 , C12N15/63 , C12N9/22 , C07K14/325
CPC分类号： C07K14/78 , A61K38/00 , A61K48/005 , A61P35/00 , C07K7/08 , C07K14/195 , C07K14/32 , C07K14/47 , C07K14/705 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/20 , C07K2319/70 , C12N5/0636 , C12N9/12 , C12N9/22 , C12N2510/00 , C12Y207/11011 , C12Y301/27003
摘要： Disclosed herein are switchable chimeric receptors, switchable chimeric receptor effector cells and chimeric receptor effector cell switches. The switchable chimeric receptor-ECs are generally T cells. The chimeric receptors have non-antibody extracellular domains that recognize a chimeric receptor binding partner on the chimeric receptor-EC switch or target cell. The chimeric receptor-ECs and switches may be used for the treatment of a disease or condition in a subject in need thereof.
摘要翻译：本文公开了可切换嵌合受体，可切换嵌合受体效应细胞和嵌合受体效应细胞开关。可切换的嵌合受体-ECs通常是T细胞。嵌合受体具有识别嵌合受体-EC开关或靶细胞上的嵌合受体结合配偶体的非抗体细胞外结构域。嵌合受体-ECs和开关可以用于治疗有需要的受试者的疾病或病症。

7. 发明申请

WO2016139643A2 MOLECULAR SENSORS 审中-公开
标题翻译：分子传感器
公开(公告)号：WO2016139643A2
公开(公告)日：2016-09-09
申请号：PCT/IB2016/051249
申请日：2016-03-04
申请人： UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
发明人： MACKERNAN, Donal , SANYAL, Shourjya
IPC分类号： G01N33/542 , A61K39/00 , C12N15/62
CPC分类号： G01N33/542 , A61K38/00 , C07K14/47 , C07K2319/55 , C07K2319/61 , C12N9/1077 , C12N9/12 , C12N15/62 , C12Y204/02036 , C12Y207/11011 , G01N21/6428 , G01N33/582 , G01N2021/6439
摘要： The invention relates to a sensor molecule for detecting a target molecule comprising: (a) a rod-like molecule L and a rod-like molecule R connected to each other by a joint molecule C to form a hinge; (b) a target binding molecule A bonded to the end of rod- like molecule L opposite to the joint molecule C; (c) a binding molecule A' bonded to the end of rod-like molecule R opposite the joint molecule C; wherein the target binding molecule A is arranged to bind to the target molecule to be detected, and binding molecule A' is arranged to bind to: i) the same target molecule as target binding molecule A; or ii) a complex of the target binding molecule A and the target; and wherein the hinge is biased into an open position, such that target binding molecule Band binding molecule A' are biased apart by the hinge. The invention further relates to nucleic acid encoding such sensors, host cells comprising such sensor, and uses and methods of such sensors.
摘要翻译：本发明涉及用于检测靶分子的传感器分子，其包含：（a）通过连接分子C彼此连接的棒状分子L和棒状分子R以形成合页; （b）与连接分子C相反的与棒状分子L末端结合的靶结合分子A; （c）与连接分子C相对的结合分子A'与棒状分子R的末端结合; 其中靶结合分子A被排列以结合待检测的靶分子，并且结合分子A'被排列以结合：i）与靶结合分子A相同的靶分子; 或ii）靶结合分子A和靶标的复合物; 并且其中铰链偏置到打开位置，使得靶结合分子带结合分子A'被铰链分开。本发明还涉及编码这种传感器的核酸，包含这种传感器的宿主细胞以及这些传感器的用途和方法。

8. 发明申请

WO2014028560A3 T-CELL REDIRECTING BISPECIFIC ANTIBODIES FOR TREATMENT OF DISEASE 审中-公开
标题翻译：用于治疗疾病的T细胞重新定向双特异性抗体
公开(公告)号：WO2014028560A3
公开(公告)日：2014-05-01
申请号：PCT/US2013054842
申请日：2013-08-14
申请人： IBC PHARMACEUTICALS INC
发明人： CHANG CHIEN-HSING , GOLDENBERG DAVID M , ROSSI EDMUND A , ROSSI DIANE
IPC分类号： A61K45/00 , A61K38/21
CPC分类号： C07K14/001 , A61K9/0019 , A61K38/00 , A61K38/1709 , A61K38/195 , A61K38/21 , A61K38/212 , A61K38/215 , A61K38/217 , A61K38/45 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K47/42 , A61K47/48215 , A61K47/48246 , A61K47/60 , A61K47/64 , A61K2039/505 , A61K2039/572 , C07K14/4702 , C07K16/18 , C07K16/2803 , C07K16/2806 , C07K16/2809 , C07K16/2812 , C07K16/2815 , C07K16/2818 , C07K16/2827 , C07K16/283 , C07K16/2833 , C07K16/2842 , C07K16/2845 , C07K16/2851 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K16/2878 , C07K16/2884 , C07K16/2887 , C07K16/289 , C07K16/2893 , C07K16/2896 , C07K16/30 , C07K16/3007 , C07K16/3053 , C07K16/3076 , C07K16/3092 , C07K16/32 , C07K16/40 , C07K16/44 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30 , C07K2319/33 , C07K2319/40 , C07K2319/735 , C07K2319/74 , C07K2319/75 , C12N9/12 , C12Y207/11001 , C12Y207/11011 , A61K2300/00
摘要： The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3 x anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The the cytotoxic immune response is enhanced by co-administration of interfon-based agents that comprise interferon-α, interferon-&bgr;, interferon-λ1, interferon-λ2 or interferon-λ3.
摘要翻译：本发明涉及T细胞重新定向复合物的组合物和方法，其具有至少一个T细胞抗原的结合位点和至少一个病变细胞或病原体上的抗原的结合位点。优选地，该复合物是DNL TM复合物。更优选地，该复合物包含双特异性抗体（bsAb）。最优选地，bsAb是抗CD3x抗CD19双特异性抗体，尽管可以使用针对其他T细胞抗原和/或疾病相关抗原的抗体。该复合物能够靶向效应T细胞以诱导与疾病相关的细胞例如癌症，自身免疫疾病或传染病的T细胞介导的细胞毒性。通过共同施用包含干扰素-α，干扰素-β，干扰素-λ1，干扰素-λ2或干扰素-λ3的基于干扰素的试剂来增强细胞毒性免疫应答。

9. 发明申请

WO2013181087A3 MULTIMERIC COMPLEXES WITH IMPROVED IN VIVO STABILITY, PHARMACOKINETICS AND EFFICACY 审中-公开
标题翻译：改善体内稳定性，药物动力学和效率的多元复合物
公开(公告)号：WO2013181087A3
公开(公告)日：2014-02-06
申请号：PCT/US2013042594
申请日：2013-05-24
申请人： IBC PHARMACEUTICALS INC
发明人： ROSSI EDMUND A , CHANG CHIEN-HSING , GOLDENBERG DAVID M
IPC分类号： A61K39/00
CPC分类号： C07K16/3092 , A61K45/06 , A61K47/48423 , A61K47/4843 , A61K47/48438 , A61K47/48484 , A61K47/48561 , A61K47/6813 , A61K47/6815 , A61K47/6817 , A61K47/6829 , A61K47/6849 , A61K2039/505 , C07K14/56 , C07K16/18 , C07K16/2803 , C07K16/2833 , C07K16/2851 , C07K16/2863 , C07K16/2887 , C07K16/3007 , C07K16/44 , C07K2317/24 , C07K2317/30 , C07K2317/32 , C07K2317/526 , C07K2317/55 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/94 , C07K2319/00 , C12N9/12 , C12N9/22 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2320/00 , C12N2320/32 , C12Y207/11011 , C12Y301/27
摘要： The present invention concerns multimeric complexes based on antibody fusion proteins comprising an AD moiety attached to the C-terminal end of each antibody light chain. The complexes further comprise effector moities attached to DDD moieties. Two copies of the DDD moiety form a dimer that binds to the AD moiety. The complexes may be trimers, pentamers, hexamers or other multimers. The effector moieties may be selected from a second antibody or antigen-binding fragment thereof, a cytokine, an interferon, a toxin, an antigen, a xenoantigen, a hapten, a protamine, a hormone, an enzyme, a ligand-binding protein, a pro-apoptotic agent and an anti-angiogenic agent. Surprisingly, attachment of the AD moiety to the C-terminal end of the antibody light chain results in improved pharmacokinetics and in vivo stability and efficacy, compared to homologous complexes wherein the AD moiety is attached to the antibody heavy chain.
摘要翻译：本发明涉及基于抗体融合蛋白的多聚体复合物，其包含连接于每个抗体轻链的C末端的AD部分。复合物还包含与DDD部分连接的效应物。 DDD部分的两个拷贝形成与AD部分结合的二聚体。络合物可以是三聚体，五聚体，六聚体或其它多聚体。效应部分可以选自第二抗体或其抗原结合片段，细胞因子，干扰素，毒素，抗原，异种抗原，半抗原，鱼精蛋白，激素，酶，配体结合蛋白，促凋亡剂和抗血管生成剂。令人惊讶的是，与其中AD部分连接到抗体重链的同源复合物相比，AD部分与抗体轻链的C-末端的连接导致改善的药代动力学和体内稳定性和功效。

10. 发明申请

WO2012009447A3 THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF 审中-公开
标题翻译： cAMP / PKA / HDAC5路径及其用途
公开(公告)号：WO2012009447A3
公开(公告)日：2012-07-19
申请号：PCT/US2011043873
申请日：2011-07-13
申请人： UNIV ROCHESTER , JIN ZHENG-GEN
发明人： JIN ZHENG-GEN
IPC分类号： A61K38/10 , A61K31/7105 , A61K39/395 , A61P9/00 , A61P9/04 , C07K7/08 , C12N15/113 , C12N15/63
CPC分类号： A61K39/39533 , A61K31/352 , A61K31/7076 , A61K31/7088 , A61K31/7105 , A61K38/10 , C07K16/40 , C12N15/1137 , C12N2310/14 , C12Y207/11011 , G01N33/5061 , G01N33/573 , G01N2333/98 , G01N2440/14 , G01N2500/04 , G01N2500/10 , G01N2800/325
摘要： The present invention provides novel uses of the cAMP/PKA/HDAC5 pathway for the treatment and prevention of myopathies.
摘要翻译：本发明提供cAMP / PKA / HDAC5途径用于治疗和预防肌病的新用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式